Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says

Oct 19 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Moscicki's Move From FDA To PhRMA About 'Best' Use Of Leadership Skills

Oct 19 2017

How Accelerated Approval Works – And How It Doesn't

Sep 29 2017

Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

Nov 14 2011

Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

Oct 17 2011

FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk

Oct 06 2017

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Biomarkers In Orphan Studies Still Need Past Experience, FDA Says

May 27 2013

Related Companies

Sarepta Therapeutics, Inc.

PTC Therapeutics, Inc.

Additional Topics

United States Rare Diseases Review Pathway Regulation BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window